Facilitating Step Therapy Protocols: Many plans use step therapy, requiring patients to try less expensive treatments first
Safety: what we know, what we dont What clinical trial safety reviews suggest The clinical safety review literature reports several reassuring signals: No meaningful increase in IGF-1 in monitored long-term studies (jofem.org) No clear negative effect on carbohydrate metabolism in testing described (contrast with full hGH) (jofem.org) No clear immunogenicity signal (e.g., anti-AOD antibodies) in the subset assessed in those trials (jofem.org) The major limitation: long-term real-world certainty is thin The problem with many peptides is not that everything is dangerousits that the certainty level is often lower than patients assume
Theres a black market production, primarily in China, that sends large amounts of these peptides to the United States with the label For research only, says Pinchas Cohen, MD, dean and distinguished professor of gerontology, medicine, and biological sciences at the USC Leonard Davis School of Gerontology, who has discovered several investigational peptides
Call your doctor for medical advice about side effects, or report them to the FDA at 1-800-FDA-1088
Some need both